T0	KEYPHRASE-NOTYPES 13 22	diagnosis
T1	KEYPHRASE-NOTYPES 26 38	Lyme disease
T2	KEYPHRASE-NOTYPES 67 78	individuals
T3	KEYPHRASE-NOTYPES 115 136	antimicrobial therapy
T4	KEYPHRASE-NOTYPES 138 143	Table
T5	KEYPHRASE-NOTYPES 152 171	successful outcomes
T6	KEYPHRASE-NOTYPES 189 214	long-term outcome studies
T7	KEYPHRASE-NOTYPES 218 236	untreated patients
T8	KEYPHRASE-NOTYPES 285 296	individuals
T9	KEYPHRASE-NOTYPES 328 335	variety
T10	KEYPHRASE-NOTYPES 339 362	clinical manifestations
T11	KEYPHRASE-NOTYPES 378 394	Lyme borreliosis
T12	KEYPHRASE-NOTYPES 403 408	point
T13	KEYPHRASE-NOTYPES 412 416	time
T14	KEYPHRASE-NOTYPES 427 449	spontaneous resolution
T15	KEYPHRASE-NOTYPES 459 468	EM lesion
T16	KEYPHRASE-NOTYPES 475 492	First line agents
T17	KEYPHRASE-NOTYPES 517 528	doxycycline
T18	KEYPHRASE-NOTYPES 530 541	amoxicillin
T19	KEYPHRASE-NOTYPES 547 564	cefuroxime axetil
T20	KEYPHRASE-NOTYPES 566 577	Doxycycline
T21	KEYPHRASE-NOTYPES 591 600	advantage
T22	KEYPHRASE-NOTYPES 615 637	antimicrobial activity
T23	KEYPHRASE-NOTYPES 649 665	phagocytophilium
T24	KEYPHRASE-NOTYPES 673 678	event
T25	KEYPHRASE-NOTYPES 684 695	coinfection
T26	KEYPHRASE-NOTYPES 710 731	Macrolide antibiotics
T27	KEYPHRASE-NOTYPES 753 772	second-line choices
T28	KEYPHRASE-NOTYPES 787 798	intolerance
T29	KEYPHRASE-NOTYPES 802 819	contraindications
T30	KEYPHRASE-NOTYPES 823 846	beta-lactam medications
T31	KEYPHRASE-NOTYPES 851 862	doxycycline
T32	KEYPHRASE-NOTYPES 876 903	cautious clinical follow-up
T33	KEYPHRASE-NOTYPES 961 973	Historically
T34	KEYPHRASE-NOTYPES 979 985	length
T35	KEYPHRASE-NOTYPES 989 998	treatment
T36	KEYPHRASE-NOTYPES 1016 1020	days
T37	KEYPHRASE-NOTYPES 1040 1058	available evidence
T38	KEYPHRASE-NOTYPES 1083 1091	duration
T39	KEYPHRASE-NOTYPES 1095 1104	treatment
T40	KEYPHRASE-NOTYPES 1110 1121	doxycycline
T41	KEYPHRASE-NOTYPES 1128 1132	days
T42	KEYPHRASE-NOTYPES 1139 1150	Retreatment
T43	KEYPHRASE-NOTYPES 1190 1201	individuals
T44	KEYPHRASE-NOTYPES 1207 1237	persistent subjective symptoms
T45	KEYPHRASE-NOTYPES 1246 1264	objective findings
T46	KEYPHRASE-NOTYPES 1268 1292	ongoing active infection
T47	KEYPHRASE-NOTYPES 1329 1347	additional courses
T48	KEYPHRASE-NOTYPES 1351 1362	antibiotics
T49	KEYPHRASE-NOTYPES 1410 1423	cephalosporin
T50	KEYPHRASE-NOTYPES 1436 1447	ceftriaxone
T51	KEYPHRASE-NOTYPES 1472 1494	antibacterial activity
T52	KEYPHRASE-NOTYPES 1503 1504	B
T53	KEYPHRASE-NOTYPES 1537 1559	clinical circumstances
T54	KEYPHRASE-NOTYPES 1583 1596	clear benefit
T55	KEYPHRASE-NOTYPES 1606 1609	use
T56	KEYPHRASE-NOTYPES 1613 1629	oral doxycycline
T57	KEYPHRASE-NOTYPES 1656 1670	4-week courses
T58	KEYPHRASE-NOTYPES 1674 1697	intravenous ceftriaxone
T59	KEYPHRASE-NOTYPES 1745 1753	patients
T60	KEYPHRASE-NOTYPES 1759 1771	Lyme disease
T61	KEYPHRASE-NOTYPES 1776 1825	unquestionable objective neurologic abnormalities
T62	KEYPHRASE-NOTYPES 1853 1861	patients
T63	KEYPHRASE-NOTYPES 1867 1901	high-degree atrioventricular block
T64	KEYPHRASE-NOTYPES 1929 1952	intravenous ceftriaxone
T65	KEYPHRASE-NOTYPES 1962 1972	completion
T66	KEYPHRASE-NOTYPES 1983 2006	21-day treatment course
T67	KEYPHRASE-NOTYPES 2016 2026	oral agent
T68	KEYPHRASE-NOTYPES 2033 2042	Placement
T69	KEYPHRASE-NOTYPES 2048 2075	permanent cardiac pacemaker
T70	KEYPHRASE-NOTYPES 2117 2122	times
T71	KEYPHRASE-NOTYPES 2151 2169	external pacemaker
T72	KEYPHRASE-NOTYPES 2187 2201	Lesser degrees
T73	KEYPHRASE-NOTYPES 2205 2216	heart block
T74	KEYPHRASE-NOTYPES 2218 2239	first-degree AV block
T75	KEYPHRASE-NOTYPES 2241 2252	PR interval
T76	KEYPHRASE-NOTYPES 2259 2263	msec
T77	KEYPHRASE-NOTYPES 2285 2296	oral agents
